SGMO Sangamo Therapeutics Inc
Price (delayed)
$1.07
Market cap
$223.25M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$210.28M
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
Highlights
The EPS is up by 49% year-on-year and by 46% since the previous quarter
Sangamo Therapeutics's net income has increased by 46% QoQ and by 46% YoY
The equity has shrunk by 71% YoY but it has soared by 65% QoQ
The quick ratio has surged by 63% since the previous quarter but it has dropped by 57% year-on-year
The gross profit has shrunk by 74% YoY
The revenue has dropped by 74% year-on-year
Key stats
What are the main financial stats of SGMO
Market
Valuations
Earnings
Shares outstanding
208.65M
Market cap
$223.25M
Enterprise value
$210.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.69
Price to sales (P/S)
4.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.02
Revenue
$52.29M
Gross profit
$52.29M
Operating income
-$140.04M
Net income
-$134.84M
EBIT
-$134.85M
EBITDA
-$124.62M
Free cash flow
-$117.11M
Per share
Balance sheet
Liquidity
EPS
-$0.74
EPS diluted
-$0.75
Free cash flow per share
-$0.56
Book value per share
$0.19
Revenue per share
$0.25
TBVPS
$0.53
Total assets
$111.26M
Total liabilities
$72.13M
Debt
$27.73M
Equity
$39.13M
Working capital
$14.97M
Debt to equity
0.71
Current ratio
1.35
Quick ratio
1.19
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
-238.3%
Gross margin
100%
Net margin
-257.9%
Operating margin
-267.8%
Return on assets
-109.2%
Return on equity
-269%
Return on invested capital
-193.3%
Return on capital employed
-198%
Return on sales
-257.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMO stock price
How has the Sangamo Therapeutics stock price performed over time
Intraday
-4.46%
1 week
-8.55%
1 month
-5.31%
1 year
-13.71%
YTD
4.9%
QTD
4.9%
Financial performance
How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$52.29M
Gross profit
$52.29M
Operating income
-$140.04M
Net income
-$134.84M
Gross margin
100%
Net margin
-257.9%
SGMO's net margin has shrunk by 108% YoY but it has soared by 87% QoQ
SGMO's operating margin has dropped by 102% year-on-year but it has surged by 87% since the previous quarter
The gross profit has shrunk by 74% YoY
The revenue has dropped by 74% year-on-year
Growth
What is Sangamo Therapeutics's growth rate over time
Valuation
What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
5.69
P/S
4.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.02
The EPS is up by 49% year-on-year and by 46% since the previous quarter
The price to book (P/B) is 128% higher than the 5-year quarterly average of 2.5 and 103% higher than the last 4 quarters average of 2.8
The equity has shrunk by 71% YoY but it has soared by 65% QoQ
The revenue has dropped by 74% year-on-year
The stock's P/S is 41% below its 5-year quarterly average of 7.2 but 3.9% above its last 4 quarters average of 4.1
Efficiency
How efficient is Sangamo Therapeutics business performance
The ROE has plunged by 169% YoY but it has grown by 20% from the previous quarter
The return on sales has dropped by 105% year-on-year but it has surged by 87% since the previous quarter
Sangamo Therapeutics's return on invested capital has shrunk by 86% YoY but it has increased by 28% QoQ
The company's return on assets has shrunk by 69% YoY but it rose by 34% QoQ
Dividends
What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMO.
Financial health
How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 54% greater than its total liabilities
The quick ratio has surged by 63% since the previous quarter but it has dropped by 57% year-on-year
The company's current ratio has shrunk by 56% YoY but it rose by 31% QoQ
SGMO's debt is 29% lower than its equity
Sangamo Therapeutics's debt to equity has surged by 173% YoY but it has decreased by 42% QoQ
The equity has shrunk by 71% YoY but it has soared by 65% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.